---
title: "Bank of America Securities Reaffirms Their Buy Rating on Ligand Pharma (LGND)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293453828.md"
description: "Bank of America Securities analyst Jason Zemansky reaffirmed a Buy rating on Ligand Pharma (LGND) with a $388 price target. This follows Citi's recent resumption of coverage, which also assigned a Buy rating and set a $387 target. Zemansky, known for his strong performance in the healthcare sector, maintains this positive outlook on the stock."
datetime: "2026-07-22T09:56:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293453828.md)
  - [en](https://longbridge.com/en/news/293453828.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293453828.md)
generator: "portal-rs"
---

# Bank of America Securities Reaffirms Their Buy Rating on Ligand Pharma (LGND)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Ligand Pharma today and set a price target of $388.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Biogen, and BridgeBio Pharma. According to TipRanks, Zemansky has an average return of 21.5% and a 60.73% success rate on recommended stocks. 

In a report released yesterday, Citi also resumed coverage with a Buy rating on the stock with a $387.00 price target.

### Related Stocks

- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)
- [Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital](https://longbridge.com/en/news/297072983.md)
- [Ranger Investment Management L.P. Acquires Shares of 257,596 Ligand Pharmaceuticals Incorporated $LGND](https://longbridge.com/en/news/296772770.md)
- [Ligand management participates in Wells Fargo Healthcare Conference fireside chat](https://longbridge.com/en/news/297032568.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**